SCHEMBL24816626

SCHEMBL24816626

COC(=O)c1ccc(-c2nnn(C)c2C(=O)O)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
KDM4E B2RXH2 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
KMT2A Q03164 1/20 0.41
P4HA1 P13674 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
HPGDS O60760 1/20 0.40
MAPT P10636 1/20 0.40
TGFBR1 P36897 2/20 0.39
GABRA5 P31644 2/20 0.39
SPR P35270 1/20 0.39
KDM6B O15054 1/20 0.39
KDM5C P41229 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
KDM3A Q9Y4C1 1/20 0.39
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30751962 1.00 MAPK1 (0.50) MAPK1KDM4EL3MBTL1RAB9ANPC1
SCHEMBL25224521 0.79 LDHA (0.35) KMT2AP4HA1P4HTM
SCHEMBL23363199 0.79 ALDH1A1 (0.42) KDM4ERAB9AKMT2AP4HA1P4HTM
SCHEMBL30309354 0.78 ADCY10 (0.35) MAPK1KDM4ERAB9ANPC1TGFBR1
SCHEMBL29757474 0.78 KDM4E (0.37) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL23384341 0.78 ADCY10 (0.35) MAPK1KDM4ERAB9ANPC1TGFBR1
SCHEMBL23362593 0.78 KDM4E (0.37) KDM4ERAB9ANPC1MAPTALDH1A1
Hydrochloric Acid SCHEMBL29757461 0.77 ADCY10 (0.35) MAPK1KDM4ERAB9ANPC1TGFBR1
Hydrochloric Acid SCHEMBL23362550 0.77 ADCY10 (0.35) MAPK1KDM4ERAB9ANPC1TGFBR1
SCHEMBL23384108 0.76 P4HA1 (0.33) KMT2AP4HA1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4337654-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-03-20 EP disclosed
CN-117295724-A LPA receptor antagonists and uses thereof 吉利德科学公司 2023-12-26 CN disclosed
US-20220411406-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2022-12-29 US disclosed
WO-2022241023-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411406-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 MAPK1 1397/4885KDM4E 2095/4885L3MBTL1 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.